Related Experiment Video
Updated: Jul 26, 2025

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques
Published on: July 5, 2018
Structural insight into CD93 recognition by IGFBP7
Abstract:
The CD93/IGFBP7 axis are key factors expressed in endothelial cells (EC) that mediate EC angiogenesis and migration. Upregulation of them contributes to tumor vascular abnormality and blockade of this interaction promotes a favorable tumor microenvironment for therapeutic interventions. However, how these two proteins associated to each other remains unclear. In this study, we solved the human CD93-IGFBP7 complex structure to elucidate the interaction between the EGF 1 domain of CD93 and the IB domain of IGFBP7. Mutagenesis studies confirmed the binding interactions and specificities. Cellular and mouse tumor studies demonstrated the physiological relevance of the CD93-IGFBP7 interaction in EC angiogenesis. Our study provides hints for development of therapeutic agents to precisely disrupt unwanted CD93-IGFBP7 signaling in the tumor microenvironment. Additionally, analysis of the CD93 full-length architecture provides insights into how CD93 protrudes on the cell surface and forms a flexible platform for binding to IGFBP7 and other ligands.
Insights
This study reveals the structural basis of the CD93-IGFBP7 interaction, crucial for endothelial cell (EC) angiogenesis and tumor vascularization. Understanding this interaction aids in developing targeted therapies for cancer by disrupting tumor microenvironment signaling.
Area of Science:
- Molecular and Cellular Biology
- Cancer Biology
- Structural Biology
Background:
- The CD93/IGFBP7 axis is critical for endothelial cell (EC) angiogenesis and migration, with upregulation contributing to tumor vascular abnormalities.
- Blocking the CD93-IGFBP7 interaction can create a therapeutic tumor microenvironment, but the precise mechanism of their association is unknown.
Approach:
- Determined the crystal structure of the human CD93-IGFBP7 complex, focusing on the interaction between CD93's EGF1 domain and IGFBP7's IB domain.
- Utilized mutagenesis studies to confirm the binding interactions and specificities between CD93 and IGFBP7.
- Conducted cellular and mouse tumor studies to validate the physiological relevance of the CD93-IGFBP7 interaction in EC angiogenesis.
Key Points:
- Elucidated the structural basis of CD93-IGFBP7 complex formation, identifying specific interaction domains.
- Confirmed the functional significance of the CD93-IGFBP7 interaction in EC angiogenesis through in vitro and in vivo experiments.
- Provided insights into the cell surface architecture of CD93 and its role as a platform for ligand binding.
Conclusions:
- The CD93-IGFBP7 interaction is a key driver of EC angiogenesis and tumor vascularization.
- Structural and functional data provide a foundation for developing targeted therapeutic agents to disrupt CD93-IGFBP7 signaling in the tumor microenvironment.
- Understanding CD93's architecture offers new perspectives on cell surface interactions and signaling pathways.
Related Concept Videos
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
TGF - β Signaling Pathway

